Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 16/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | F10 | P00742 | 2/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.44 |
| ▸ | F9 | P00740 | 1/20 | 0.44 |
| ▸ | PLAT | P00750 | 1/20 | 0.44 |
| ▸ | F11 | P03951 | 1/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.44 |
| ▸ | F7 | P08709 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | MASP2 | O00187 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6079249 | 0.83 | F2 (0.57) | F2CYP3A4F10PRSS1PRSS3 | |
| SCHEMBL6079229 | 0.83 | F2 (0.57) | F2CYP3A4F10PRSS1PRSS3 | |
| SCHEMBL6076705 | 0.78 | CYP3A4 (0.70) | F2CYP3A4F10PRSS1PRSS3 | |
| SCHEMBL6078453 | 0.78 | F2 (0.58) | F2CYP3A4F10PRSS1PRSS3 | |
| SCHEMBL6078656 | 0.75 | F2 (0.47) | F2CYP3A4F10PRSS1PRSS3 | |
| SCHEMBL6079191 | 0.75 | F2 (0.60) | F2CYP3A4F10PRSS1PRSS3 | |
| SCHEMBL6079393 | 0.75 | CYP3A4 (0.72) | F2CYP3A4F10PRSS1PRSS3 | |
| SCHEMBL6079352 | 0.74 | F2 (0.46) | F2CYP3A4F11ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL6079141 | 0.74 | F2 (0.46) | F2CYP3A4F10PRSS1PRSS3 | |
| SCHEMBL6076574 | 0.74 | F2 (0.50) | F2CYP3A4F11ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144899-B2 | Thrombin inhibitors | MERCK & CO., INC. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20040073025-A1 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. | 2004-04-15 | — | — | US | disclosed |
| WO-2002064559-A2 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073025-A1 | Thrombin inhibitors | F2, F11, F10 | F2 1/4885CYP3A4 2153/4885F10 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.